Midori Shima

14.9k total citations · 6 hit papers
404 papers, 10.3k citations indexed

About

Midori Shima is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Midori Shima has authored 404 papers receiving a total of 10.3k indexed citations (citations by other indexed papers that have themselves been cited), including 339 papers in Hematology, 109 papers in Genetics and 43 papers in Molecular Biology. Recurrent topics in Midori Shima's work include Hemophilia Treatment and Research (295 papers), Blood Coagulation and Thrombosis Mechanisms (165 papers) and Platelet Disorders and Treatments (148 papers). Midori Shima is often cited by papers focused on Hemophilia Treatment and Research (295 papers), Blood Coagulation and Thrombosis Mechanisms (165 papers) and Platelet Disorders and Treatments (148 papers). Midori Shima collaborates with scholars based in Japan, United States and United Kingdom. Midori Shima's co-authors include Keiji Nogami, Akira Yoshioka, Evgueni L. Saenko, Tomoko Matsumoto, Dorothea Scandella, Gallia G. Levy, Kenichi Ogiwara, Christophe Schmitt, Johnny Mahlangu and Johannes Oldenburg and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and SHILAP Revista de lepidopterología.

In The Last Decade

Midori Shima

381 papers receiving 9.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

2017 759 citations Johannes Oldenburg, Johnny Mahlangu et al. profile →
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

2018 503 citations Johnny Mahlangu, Johannes Oldenburg et al. profile →
Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A

2016 326 citations Midori Shima, Hideji Hanabusa et al. profile →
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study

2019 273 citations Steven W. Pipe, Midori Shima et al. profile →
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors

2019 263 citations Guy Young, Tiffany Chang et al. Blood profile →
International recommendations on the diagnosis and treatment of acquired hemophilia A

2020 183 citations Midori Shima, Víctor Jiménez‐Yuste et al. profile →

Peers

Countries citing papers authored by Midori Shima

Since Specialization

Citations

This map shows the geographic impact of Midori Shima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Midori Shima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Midori Shima more than expected).

Fields of papers citing papers by Midori Shima

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Midori Shima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Midori Shima. The network helps show where Midori Shima may publish in the future.

Co-authorship network of co-authors of Midori Shima

This figure shows the co-authorship network connecting the top 25 collaborators of Midori Shima. A scholar is included among the top collaborators of Midori Shima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Midori Shima. Midori Shima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Force‐sensing treadmill gait analysis system can detect gait abnormalities in haemophilia patients without arthropathy 2024 ·Haemophilia ·(unknown), Asuka Sakata, Yusuke Inagaki, Suguru Harada, Kohei Tatsumi, Naoki Matsumoto, Kenichi Ogiwara, Koji Yada, Yasushi Yoshimura, Akira Kido, Yasuhito Tanaka, Midori Shima, Keiji Nogami	1
2	International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology 2024 ·Journal of Thrombosis and Haemostasis ·Suely Meireles Rezende, Ignacio Neumann, Pantep Angchaisuksiri, (unknown), Ana Boban, Adam Cuker, Julie Curtin, Karin Fijnvandraat, Samantha C. Gouw, Roberta Gualtierotti, Michael Makris, (unknown), Niamh O’Connell, Renu Saxena, Midori Shima, Runhui Wu, Frits R. Rosendaal	13
3	An ecological association of number of civil servants and physicians with prefectural-level rapid COVID-19 vaccination of older people in Japan 2023 ·Environmental Health and Preventive Medicine ·Kimiko Tomioka, Midori Shima, Keigo Saeki	1
4	Generation of functional liver sinusoidal endothelial-like cells from human bone marrow-derived mesenchymal stem cells 2023 ·Regenerative Therapy ·Seiji Mitani, Yu Onodera, Chihiro Hosoda, (unknown), Asuka Sakata, Midori Shima, Kohei Tatsumi	3
5	AOZORA: long-term safety and joint health in paediatric persons with haemophilia A without factor VIII inhibitors receiving emicizumab – protocol for a multicentre, open-label, phase IV clinical study 2022 ·BMJ Open ·Midori Shima, Hideyuki Takedani, (unknown), Masashi Taki, Akira Ishiguro, (unknown), (unknown), (unknown), Seitaro Yoshida, Keiji Nogami	4
6	Successful unrelated cord blood transplantation for Diamond–Blackfan anemia 2021 ·Pediatrics International ·(unknown), Takashi Ishihara, Satoshi Ochi, Midori Shima, Keiji Nogami	1
7	The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies 2021 ·Haemophilia ·Mark W. Skinner, Claude Négrier, Ido Paz‐Priel, Sammy Chebon, Víctor Jiménez‐Yuste, Michael U. Callaghan, Michaela Lehle, Markus Niggli, Johnny Mahlangu, Amy D. Shapiro, Midori Shima, Avrita Campinha‐Bacote, Gallia G. Levy, Johannes Oldenburg, Sylvia von Mackensen, Steven W. Pipe	34
8	Health‐related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study 2020 ·Haemophilia ·Maria Elisa Mancuso, Johnny Mahlangu, Robert F. Sidonio, Peter C. Trask, Marianne Uguen, Tiffany Chang, Midori Shima, Guy Young, Johannes Oldenburg, Sylvia von Mackensen	18
9	Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies 2020 ·Blood ·Michael U. Callaghan, Claude Négrier, Ido Paz‐Priel, Tiffany Chang, Sammy Chebon, Michaela Lehle, Johnny Mahlangu, Guy Young, Rebecca Kruse‐Jarres, Maria Elisa Mancuso, Markus Niggli, Monet Howard, Nives Selak Bienz, Midori Shima, Víctor Jiménez‐Yuste, Christophe Schmitt, Elina Asikanius, Gallia G. Levy, Steven W. Pipe, Johannes Oldenburg	170
10	How to recover lost vaccine acceptance? A multi-center survey on HPV vaccine acceptance in Japan 2020 ·Journal of Infection and Chemotherapy ·(unknown), (unknown), Taito Kitano, (unknown), Masahiro Takeyama, Midori Shima	15
11	Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4) 2020 ·Blood ·Michael U. Callaghan, Claude Négrier, Ido Paz‐Priel, Tiffany Chang, Sammy Chebon, Michaela Lehle, Johnny Mahlangu, Guy Young, Rebecca Kruse‐Jarres, Maria Elisa Mancuso, Markus Niggli, Peter Kuebler, Nives Selak Bienz, Midori Shima, Víctor Jiménez‐Yuste, Christophe Schmitt, Elina Asikanius, Gallia G. Levy, Steven W. Pipe, Johannes Oldenburg	4
12	Hemostatic function in hyperfibrinolytic disseminated intravascular coagulation 2019 ·Pediatrics International ·Takashi Ishihara, Keiji Nogami, (unknown), Kenichi Ogiwara, Satoshi Ochi, Masaharu Yamazaki, Midori Shima	9
13	Disordered hemostasis associated with severely depressed fibrinolysis demonstrated using a simultaneous thrombin and plasmin generation assay during L‐asparaginase induction therapy in pediatric acute lymphoblastic leukemia 2019 ·Pediatric Blood & Cancer ·Takashi Ishihara, Keiji Nogami, Satoshi Ochi, Toshiaki Ishida, Yoshiyuki Kosaka, Akihisa Sawada, Masami Inoue, Shinya Osone, Toshihiko Imamura, Hajime Hosoi, Midori Shima	8
14	Emicizumab Prophylaxis Administered Once-weekly or Every Two Weeks Provides Effective Bleed Prevention in Persons with Hemophilia A (PwHA) without Inhibitors - Results from the Phase III HAVEN 3 Study 2019 ·Hämostaseologie ·Johannes Oldenburg, Johnny Mahlangu, Ido Paz‐Priel, Claude Négrier, Markus Niggli, Maria Elisa Mancuso, Christophe Schmitt, Víctor Jiménez‐Yuste, Christine L. Kempton, Christophe Dhalluin, Michael U. Callaghan, Willem Buján, Midori Shima, Joanne I. Adamkewicz, Elina Asikanius, Gallia G. Levy, Rebecca Kruse‐Jarres	2
15	Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI‐deficient plasma in vitro 2018 ·Journal of Thrombosis and Haemostasis ·(unknown), Keiji Nogami, Koji Yada, Kenichi Ogiwara, Shoko Furukawa, Tetsuhiro Soeda, Takehisa Kitazawa, Midori Shima	12
16	Bleeding Events and Safety Outcomes in Pediatric Persons with Hemophilia A with Inhibitors: The First Non-Interventional Study (NIS) from a Real-World Setting 2017 ·Blood ·Johannes Oldenburg, Midori Shima, Rebecca Kruse‐Jarres, Elena Santagostino, Johnny Mahlangu, Nives Selak Bienz, Sammy Chebon, Elina Asikanius, Gallia G. Levy	2
17	Emicizumab Prophylaxis in Adolescent/Adult Patients with Hemophilia A Previously Receiving Episodic or Prophylactic Bypassing Agent Treatment: Updated Analyses from the HAVEN 1 Study 2017 ·Blood ·Maria Elisa Mancuso, Michael U. Callaghan, Rebecca Kruse‐Jarres, Christine L. Kempton, Jin Xu, Olivier Catalani, Elina Asikanius, Gallia G. Levy, Midori Shima, Guy Young, Johannes Oldenburg	14
18	A first-in-human phase 1 study of ACE910, a novel factor VIII–mimetic bispecific antibody, in healthy subjects 2015 ·Blood ·Naoki Uchida, Takehiko Sambe, Koichiro Yoneyama, (unknown), Takehiko Kawanishi, Shinichi Kobayashi, Midori Shima	200
19	Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti‐C2 antibody inhibiting allogeneic but not autologous factor VIII activity 2015 ·Journal of Thrombosis and Haemostasis ·Koji Yada, Keiji Nogami, Masahiro Takeyama, Kenichi Ogiwara, Hironao Wakabayashi, Midori Shima	4
20	Long-term safety and efficacy of recombinant activated factor VII (NovoSeven) in haemophilia patients with inhibitors: interim post marketing study analysis of 5 patient exposure years 2006 ·Japanese Journal of Thrombosis and Hemostasis ·Akira Shirahata, Toshiaki Oka, Katsuyuki Fukutake, Morio Arai, Hideji Hanabusa, Masashi Taki, Takeshi Nagao, J Mimaya, Nobuhiko Haga, Junki Takamatsu, Tadashi Kamiya, Midori Shima, Eizo Kakishita, Hideyuki Takedani, Noboru Takata, Masao Kobayashi, Tatsumi Uchida, (unknown), Akira Yoshioka	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact